N-(diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: N-(diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide
• 英文别名: N-carbamimidoyl-2-(2,5-diphenylpyrrol-1-yl)acetamide
• 化学式: C₁₉H₁₈N₄O
• 分子量: 318.378
• InChiKey: WVLDNAVUCUAGDP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  86.4
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1,2-联苯甲酰乙烷 在 lithium hydroxide 、 对甲苯磺酸 、 N,N'-羰基二咪唑 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 103.0h， 生成 N-(diaminomethylene)-2,5-diphenyl-1H-pyrrole-1-acetamide
  参考文献：
  名称：

  Acylguanidines as Small-Molecule β-Secretase Inhibitors

  摘要：

  BACE1 is an aspartyl protease responsible for cleaving amyloid precursor protein to liberate A beta, which aggregates leading to plaque deposits implicated in Alzheimer's disease. We have identified small-molecule acylguanidine inhibitors of BACE1. Crystallographic studies show that these compounds form unique hydrogen-bonding interactions with the catalytic site aspartic acids and stabilize the protein in a flap-open conformation. Structure-based optimization led to the identification of potent analogs, such as 10d (BACE1 IC50 = 110 nM).

  DOI：

  10.1021/jm0607451

文献信息

• Azolylacylguanidines as beta-secretase inhibitors
  申请人：Cole Cecil Derek

  公开号：US20060183790A1

  公开（公告）日：2006-08-17

  The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种化合物，其化学式为I。本发明还提供了利用该化合物抑制β-分泌酶(BACE)、治疗β-淀粉样沉积和神经原纤维缠结的方法。
• AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS
  申请人：Cole Derek Cecil

  公开号：US20080287424A1

  公开（公告）日：2008-11-20

  The present invention provides an azolylacylquanidine compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

  本发明提供了一种式子为I的咪唑基酰基喹啉胺化合物。本发明还提供了使用该化合物的方法，以抑制β-分泌酶（BACE）并治疗β-淀粉样沉积和神经原纤维缠结。
• Acylguanidine inhibitors of β-secretase: Optimization of the pyrrole ring substituents extending into the S1 and S3 substrate binding pockets
  作者：Derek C. Cole、Joseph R. Stock、Rajiv Chopra、Rebecca Cowling、John W. Ellingboe、Kristi Y. Fan、Boyd L. Harrison、Yun Hu、Steve Jacobsen、Lee D. Jennings、Guixian Jin、Peter A. Lohse、Michael S. Malamas、Eric S. Manas、William J. Moore、Mary-Margaret O’Donnell、Andrea M. Olland、Albert J. Robichaud、Kristine Svenson、JunJun Wu、Eric Wagner、Jonathan Bard

  DOI：10.1016/j.bmcl.2007.12.010

  日期：2008.2

  Proteolytic cleavage of amyloid precursor protein by beta-secretase (BACE-1) and gamma-secretase leads to formation of beta-amyloid (A beta) a key component of amyloid plaques, which are considered the hallmark of Alzheimer's disease. Small molecule inhibitors of BACE-1 may reduce levels of A beta and thus have therapeutic potential for treating Alzheimer's disease. We recently reported the identification of a novel small molecule BACE-1 inhibitor N-[2-(2,5-diphenyl-pyrrol-1-yl)-acetyl]guanidine (3.a.1). We report here the initial hit-to-lead optimization of this hit and the SAR around the aryl groups occupying the S-1 and S-2' pockets leading to submicromolar BACE-1 inhibitors. (C) 2007 Elsevier Ltd. All rights reserved.
• AZOLYLACYLGUANIDINES AS ß-SECRETASE INHIBITORS
  申请人：Wyeth

  公开号：EP1848692A1

  公开（公告）日：2007-10-31
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.